Maplight Therapeutics Inc. share price logo

Maplight Therapeutics Inc. Share Price

NASDAQ: MPLT

Small Cap

$16.99

-0.09

(-0.53%)

as on

Maplight Therapeutics Inc. Stock Performance

as on March 25, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $16.30
    $17.36
    downward going graph

    4.06%

    Downside

    2.18%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Maplight Therapeutics Inc. share price movements today

Previous Close
$17.08
Open
$17.00
Volume
441.2K
Day's Low - High
$16.30 - $17.36

Maplight Therapeutics Inc. Historical Returns

1 Month Return
-3.12 %
3 Month Return
-5.74 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Maplight Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Maplight Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$796.8M

EPS (TTM)

-9.98

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

0.00%

Maplight Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Maplight Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Maplight Therapeutics Inc. image
Maplight Therapeutics Inc.
NA$796.8MNANA0.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.4B126.75%133.418.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.3B112.49%29.6832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.6BNA1115.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$77.5B58.91%17.6731.41%

Maplight Therapeutics Inc. Stock’s Investor Sentiment and Interest

Search interest for Maplight Therapeutics Inc. Stock has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-50% versus previous 30 day period

Maplight Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2024
Dec 2024
Sep 2025
Total Revenue
-
-
-
Gross Profit
-
-
0
Operating Income
-20
-22
-31
EBITDA
-20
-22
-31
Interest Expense
-
-
-
Depreciation
0
0
0
Income Before Tax
-19
-21
-29
Income Tax Expense
-
-
-
Net Income
-19
-21
-29
Net Profit Margin
0.00%
0.00%
0.00%

Maplight Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Total Revenue
Gross Profit
Operating Income
EBITDA
Interest Expense
Depreciation
Income Before Tax
Income Tax Expense
Net Income
Net Profit Margin

Maplight Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
-18
-18
-19
-21
-22
-29
-29
Operating Cash Flow
-19
-17
-19
-21
-25
-33
-31
Investing Cash Flow
0
-121
8
32
37
17
-135
Financing Cash Flow
119
-1
0
0
0
0
198
Change in Cash
179
-179
-11
10
50
-16
30

Maplight Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2023
Dec 2024
Net Income
-55
-77
Operating Cash Flow
-52
-78
Investing Cash Flow
0
-80
Financing Cash Flow
104
118
Change in Cash
52
-41

Insights on Maplight Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, MPLT stock has moved down by -3.1%

About Maplight Therapeutics Inc.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.
OrganisationMaplight Therapeutics Inc.
Headquarters800 Chesapeake Drive, Redwood City, CA, United States, 94063
CEODr. Christopher A. Kroeger M.B.A., M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Maplight Therapeutics Inc.

Name

Title

Mr. Vishwas Setia

Chief Financial Officer

Dr. Karoly Nikolich Ph.D.

Founder

Dr. James Woodruff Lillie Ph.D.

Chief Scientific Officer

Mr. Kristopher L. Hanson J.D.

General Counsel & Secretary

Dr. Anatol Kreitzer Ph.D.

Chief Discovery Officer

Dr. Robert C. Malenka M.D., Ph.D.

Co-Founder, Director & Member of Scientific Advisory Board

Dr. Erin Pennock Foff M.D., Ph.D.

Chief Medical Officer

Dr. Karl Deisseroth M.D., Ph.D.

Co-Founder & Member of Scientific Advisory Board

Mr. Jonathan Gillis CPA

Chief Administrative & Accounting Officer

Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D.

Founder, President, CEO & Director

FAQs

What is Maplight Therapeutics Inc. share price today?

Maplight Therapeutics Inc. share price today is $16.99 as on at the close of the market. Maplight Therapeutics Inc. share today touched a day high of $17.36 and a low of $16.3.

What is the 52 week high and 52 week low for Maplight Therapeutics Inc. share?

Maplight Therapeutics Inc. share touched a 52 week high of $ on and a 52 week low of $ on . Maplight Therapeutics Inc. stock price today i.e. is closed at $16.99,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Maplight Therapeutics Inc.'s market capitalisation today?

Maplight Therapeutics Inc. market capitalisation is $0.00T as on .

How to invest in Maplight Therapeutics Inc. Stock (MPLT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Maplight Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Maplight Therapeutics Inc. Shares that will get you 0.0883 shares as per Maplight Therapeutics Inc. share price of $16.99 per share as on March 25, 2026 at 1:29 am IST.

What is the minimum amount required to buy Maplight Therapeutics Inc. Stock (MPLT) from India?

Indian investors can start investing in Maplight Therapeutics Inc. (MPLT) shares with as little as ₹93.734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹937.34 in Maplight Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Maplight Therapeutics Inc. share’s latest price of $16.99 as on March 25, 2026 at 1:29 am IST, you will get 0.5886 shares of Maplight Therapeutics Inc.. Learn more about fractional shares .